MRC Technology Enters Into an Exclusive License Agreement With Genentech

July 11, 2010

LONDON, July 12, 2010 /PRNewswire/ — MRC Technology (UK) announced today
that it has entered into an agreement with Genentech, Inc., a wholly owned
member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for an exclusive
licence to a series of small molecule drug candidates for the potential
treatment of neurological disease.

This is the first small molecule chemistry programme to come out of MRC
Technology’s Centre for Therapeutics Discovery (CTD) and the first major
small molecule collaboration the CTD has formed with an industry partner.

Under the terms of the agreement, MRC Technology will receive an upfront
payment and is eligible to receive clinical development milestone payments
and royalties on sales. Full financial terms and the target of the small
molecule project have not been disclosed.

Working with investigators funded through UK’s Medical Research Council,
MRC Technology’s CTD initiated a small molecule drug discovery programme that
included medicinal chemistry, biology, analytical and DMPK Computational
Chemistry. CTD was formed one year ago from the MRC Technology Drug Discovery
Group, expanding its capability and capacity to provide the UK with a
national drug discovery resource with the critical mass to progress high
quality projects towards clinical benefit. MRC Technology works with targets
not only from the UK’s Medical Research Council but has a pipeline of targets
from academic organisations worldwide.

Dr Dave Tapolczay, CEO of MRC Technology, said, “We are delighted that we
have been able to partner this programme with Genentech, and extremely
pleased that the terms of our agreement reflect the value of the small
molecule drug discovery programme and support our innovative business model.”

“This licensing deal is just one example of the innovative ways that MRC
Technology is now exploiting both its small molecule and therapeutic antibody
capabilities. We can collaborate with other technology transfer
organizations, on a shared risk basis, to develop small molecule drug
discovery programmes and targets with therapeutic potential. When the
resulting clinical candidate is subsequently licensed, both parties will not
only accomplish their translational research aims, but also share in its
commercial success going forward.”

Notes to Editors

About Genentech

Founded more than 30 years ago, Genentech is a leading biotechnology
company that discovers, develops, manufactures and commercializes medicines
to treat patients with serious or life-threatening medical conditions. The
company, a member of the Roche Group, has headquarters in South San
Francisco, California
. For additional information about the company, please
visit http://www.gene.com.

About Medical Research Council Technology (MRC Technology)

MRC Technology is the exclusive commercialisation agent for the UK
Medical Research Council, working to translate cutting edge scientific
discoveries into commercial products. It is now the most successful academic
healthcare technology transfer organization in the world (AUTM Licensing
survey 2007).

MRC Technology bridges the gap between innovative basic science and
making medicine. It works to provide drug-like candidate molecules to
innovative new drug targets, and to translate innovative antibody-based drug
targets into potent and selective therapeutic antibody candidates giving
pharmaceutical and biotechnology companies new starting points for drug
discovery and development, based on MRC advances in science.

MRC Technology’s Centre for Therapeutics Discovery (CTD) collaborates
with academic scientists to develop drug discovery projects targeting
diseases for which there is significant unmet need. It applies state of the
art computational and medicinal chemistry to produce “drug-like” molecules
with the potential to become therapies. Scientists from academia benefit from
the wealth of the CTD’s expertise including provision of tool compounds and
reagents (including monoclonal antibodies) for further target validation and
characterization studies, in silico screening, and access to medicinal
chemistry, screening technologies and ADMET. CTD will also provide academia
access to its hybridoma production capability and its extensive antibody
engineering and expression expertise as well as its core antibody
humanization skills. This initiative will also enable UK scientists to tap
into MRC’s recently announced Developmental Pathway Funding Scheme (DPFS) and
collaborate with a high quality drug discovery capability whilst retaining
existing IP ownership.

    Media contact:

    Medical Research Council Technology:
    Jan Coates
    Business Development Officer
    MRC Technology
    E-mail: jan.coates@tech.mrc.ac.uk
    Phone: +44(0)20-7391-2773
    Website: http://www.mrctechnology.org

SOURCE MRC Technology

Source: newswire

comments powered by Disqus